Contents

13 Mumps

Key information

Mode of transmission Airborne droplets or direct contact with infected respiratory tract secretions or urine.
Incubation period About 16 to 18 days, ranging from 12 to 25 days.
Period of communicability From 7 days before the onset of parotitis until 9 days after the onset of illness.
Funded vaccine A live-attenuated vaccine (MMR II), containing measles, mumps and rubella viruses.
Funded vaccine indications and schedule Children at ages 15 months and 4 years.

Adults who are susceptible to one or more of measles, mumps and rubella.

For (re-)vaccination following immunosuppression (seek specialist advice).
Vaccine efficacy/effectiveness 64–66 percent effective against laboratory-confirmed mumps after 1 dose and 83–88 percent after 2 vaccine doses.
Egg allergy Egg allergy, including anaphylaxis, is not a contraindication for MMR vaccine.
Adverse events to vaccine MMR vaccine is generally well tolerated. The risk of adverse reactions to MMR vaccine is low, compared to the risk of complications from mumps disease.